Krystal Biotech Inc. (KRYS)
NASDAQ · Healthcare
Krystal Biotech Inc. EBITDA 2020–2025
Krystal Biotech Inc. annual/quarterly ebitda history and growth rate from 2020 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Krystal Biotech Inc. ebitda for the quarter ending March 31, 2026 was 55.4 M, a 46.56% increase year-over-year.
- Krystal Biotech Inc. ebitda for the twelve months ending March 31, 2026 was 185.3 M.
- Krystal Biotech Inc. annual ebitda for 2025 was 167.8 M, a 13.86% increase from 2024.
- Krystal Biotech Inc. annual ebitda for 2024 was 147.4 M, a 311.81% decrease from 2023.
- Krystal Biotech Inc. annual ebitda for 2023 was -69.6 M, a 38.04% decrease from 2022.
- Krystal Biotech Inc. annual ebitda for 2022 was -112.3 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Krystal Biotech Inc. EBITDA — FAQ
Krystal Biotech Inc. (KRYS) ebitda over the last 6 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see KRYS's ebitda history?
The chart and table above show Krystal Biotech Inc.'s ebitda by year and by quarter, including the growth rate.